Technology
Health
Biotechnology

Merus

$12.95
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.35 (-2.60%) Today
-$0.19 (-1.44%) After Hours

Why Robinhood?

You can buy or sell Merus and other stocks, options, ETFs, and crypto commission-free!

About

Merus N.V. Common Shares, also called Merus, is a clinical-stage immune-oncology company, which engages in the discovery and development of bi-specific antibody therapeutics. Read More Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg on June 16, 2003 and is headquartered in Utrecht, Netherlands.

Employees
98,000
Headquarters
Utrecht, Utrecht
Founded
2003
Market Cap
306.91M
Price-Earnings Ratio
Dividend Yield
Average Volume
42.74K
High Today
$13.55
Low Today
$12.71
Open Price
$13.53
Volume
7.56K
52 Week High
$26.74
52 Week Low
$11.00

Collections

Technology
Health
Biotechnology
Medical
Therapy
2016 IPO
Europe (Non-UK)
Europe

News

Yahoo FinanceMay 9

Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors

UTRECHT, Netherlands, May 09, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, today announced that the first patient has been treated in its Phase 1 trial evaluating safety, tolerability, and preliminary efficacy of MCLA-145 for the treatment of patients with advanced solid tumors.

174

Earnings

-$0.96
-$0.65
-$0.33
-$0.02
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
-$0.02 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.